Erratum to: Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium

被引：0
|
作者：
Thitima Kongnakorn
Tereza Lanitis
Lieven Annemans
Vincent Thijs
Sophie Marbaix
机构：
[1] Evidera,Laboratory of Neurobiology
[2] Evidera,Experimental Neurology and Leuven Research Institute for Neurodegenerative Diseases (LIND)
[3] Ghent University (Ugent),Department of Neurology
[4] Brussels University (VUB),undefined
[5] Vesalius Research Center,undefined
[6] VIB,undefined
[7] University of Leuven (KU Leuven),undefined
[8] University Hospital Leuven,undefined
[9] Pfizer,undefined
来源：
Clinical Drug Investigation | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：753 / 753
相关论文
共 50 条
  • [1] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Thitima Kongnakorn
    Tereza Lanitis
    Lievens Annemans
    Vincent Thijs
    Sophie Marbaix
    Clinical Drug Investigation, 2014, 34 : 709 - 721
  • [2] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Kongnakorn, Thitima
    Lanitis, Tereza
    Annemans, Lievens
    Thijs, Vincent
    Marbaix, Sophie
    CLINICAL DRUG INVESTIGATION, 2014, 34 (10) : 709 - 721
  • [3] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium (vol 34, pg 709, 2014)
    Kongnakorn, Thitima
    Lanitis, Tereza
    Annemans, Lieven
    Thijs, Vincent
    Marbaix, Sophie
    CLINICAL DRUG INVESTIGATION, 2014, 34 (10) : 753 - 753
  • [4] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS
    de Andres-Nogales, F.
    Oyaguez, I
    Suarez, C.
    Lopez-Sendon, J. L.
    Gonzalez-Juanatey, J. R.
    Suarez, J.
    Polanco, C.
    VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [5] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Canal Fontcuberta, G.
    Escolar Albaladejo, G.
    Betegon Nicolas, L.
    de Salas-Cansado, M.
    Rubio-Rodriguez, D.
    Rubio-Terres, G.
    VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
  • [6] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS
    de Andres-Nogales, F.
    Gay-Pobes, P. R.
    Ines, M.
    Polanco Sanchez, C.
    Alves, D.
    Oyaguez, I
    VALUE IN HEALTH, 2019, 22 : S549 - S550
  • [7] COST EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS OTHER NOACS FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
    Pradelli, L.
    Calandriello, M.
    Di Virgilio, R.
    Bellone, M.
    Tubaro, M.
    VALUE IN HEALTH, 2014, 17 (07) : A487 - A487
  • [8] Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
    Hersi, Ahmad S.
    Osenenko, Katherine M.
    Kherraf, Sid Ahmed
    Aziz, Ayman Abdel
    Sambrook, Robert Joseph
    ANNALS OF SAUDI MEDICINE, 2019, 39 (04) : 265 - 278
  • [9] Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation
    Lip, G. Y. H.
    Kongnakorn, T.
    Lanitis, T.
    Phatak, H.
    Liu, J. X. C.
    Kuznik, A.
    Lawrence, J.
    Dorian, P.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1108 - 1109
  • [10] Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain
    Escolar-Albaladejo, Gines
    Baron-Esquivias, Gonzalo
    Luis Zamorano, Jose
    Betegon-Nicolas, Lourdes
    Canal-Fontcuberta, Cristina
    de Salas-Cansado, Marina
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    ATENCION PRIMARIA, 2016, 48 (06): : 394 - 405
12345